Leptomeningeal Metastasis
Conditions
Brief summary
Leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. No efficient treatment exists. Recent data suggest that craniospinal radiotherapy lead to superior survival and CNS control compared to focal photon radiotherapy. We want to offer Danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle
Detailed description
Patients must be referred from Danish Departments of Oncology with radiotherapy service. Patients with leptomeningeal metastasis from both solid and hematological cancers will be offered proton radiotherapy with 30 Gy in 10 fractions to the entire craniospinal axis. Patients will be followed with registration of side effects, neurology and MRI scans every 3 months until 1 year.
Interventions
RADIATIONCSI
30 Gy in 10 fractions to CNS
Sponsors
University of Aarhus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metastasis to the leptomeningeal space (LM) surrounding the brain and/ or spinal cord * Metastasis verified by MRI or CSF cytology * Karnofsky \>=60 (requiring some help, can take care of most personal requirements) * Adequate bone marrow function * Haemoglobin \> 5 mmol/l * Absolute neutrophil count \>1 10\^9/l * Platelet count \> 100 10\^9/l * Patient consent * Female subjects must either be of non-reproductive potential ( ≥ 60 years old, or with no menses for \>1 year without an alternative medical cause\], OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a pregnancy test within 2 weeks prior to starting treatment. * Patient at reproductive potential must agree to practice an effective contraceptive method.
Exclusion criteria
* • Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances (Yang) * Patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy * Patient with extensive systemic disease and without reasonable systemic treatment options * Patient who is unable to undergo MRI brain and spine with gadolinium contrast * Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CNS control | 6 months | local control |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 1 year | actuarial |
| CNS-PFS dependent on tumor site | 1 year | progression free survival, actuarial |
| Symptomatology | 1 year | New symptoms, CTC AE 5.0 grade \>=3 |
Countries
Denmark
Contacts
Primary ContactKenneth Jensen, PhD
Backup ContactDorte Winther, M.H.Sc.
Outcome results
None listed